Peng Yingqian, Tang Luosheng, Zhou Yedi
Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, China.
Ophthalmic Res. 2017;58(4):217-226. doi: 10.1159/000479157. Epub 2017 Sep 1.
Compared to intravitreal injection, subretinal injection has more direct effects on the targeting cells in the subretinal space, which provides a new therapeutic method for vitreoretinal diseases, especially when gene therapy and/or cell therapy is involved. To date, subretinal delivery has been widely applied by scientists and clinicians as a more precise and efficient route of ocular drug delivery for gene therapies and cell therapies including stem cells in many degenerative vitreoretinal diseases, such as retinitis pigmentosa, age-related macular degeneration, and Leber's congenital amaurosis. However, clinicians should be aware of adverse events and possible complications when performing subretinal delivery. In the present review, the subretinal injection used in vitreoretinal diseases for basic research and clinical trials is summarized and described. Different methods of subretinal delivery, as well as its benefits and challenges, are also briefly introduced.
与玻璃体内注射相比，视网膜下注射对视网膜下间隙中的靶向细胞具有更直接的作用，这为玻璃体视网膜疾病提供了一种新的治疗方法，尤其是在涉及基因治疗和/或细胞治疗时。迄今为止，视网膜下给药已被科学家和临床医生广泛应用，作为一种更精确、高效的眼部给药途径，用于许多退行性玻璃体视网膜疾病的基因治疗和细胞治疗，包括干细胞治疗，如色素性视网膜炎、年龄相关性黄斑变性和莱伯先天性黑蒙。然而，临床医生在进行视网膜下给药时应注意不良事件和可能的并发症。在本综述中，总结并描述了用于玻璃体视网膜疾病基础研究和临床试验的视网膜下注射。还简要介绍了不同的视网膜下给药方法及其益处和挑战。
